STERIS plc
STESTERIS wins by embedding itself into the daily workflow of hospitals and device makers, turning safety compliance into recurring revenue.
Because boring, mission-critical businesses often make the most durable 20-year investments.
Business Model
Devices plus services
It sells sterilization equipment and then earns recurring revenue maintaining and servicing it.
Economic Engine
High cash generation
Strong margins and cash conversion turn steady healthcare demand into dependable cash.
Long-Term Lens
Ecosystem durability
The key question is whether STERIS can stay embedded in hospital and pharma workflows for decades.
BinaPrint Snapshot
Style
Harvest
Fitness
Mixed
Updated Mar 8, 2026
On this page
Company Story
How do STERIS plc's business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“A steady cash-generating sterilization franchise that can compound slowly and reliably as healthcare complexity rises.”
What does STERIS plc actually do?
STERIS plc makes and services the equipment that keeps medical environments sterile and safe.
- Builds sterilizers and infection prevention equipment for hospitals
- Provides sterilization services to medical device and pharmaceutical companies
- Maintains and services installed equipment over many years
Why it matters
Infection control is non optional
Hospitals and drug makers cannot operate without meeting strict safety standards, making demand resilient.
How does STERIS plc make money?
STERIS makes money by selling equipment upfront and then earning ongoing revenue from service, parts, and outsourced sterilization.
- Equipment sales create the installed base
- Service contracts generate recurring revenue
- Outsourced sterilization brings repeat volume from device makers
Economic clue
14.3% free cash flow margin
Healthy cash margins show the business is not just selling hardware, it is earning profitable follow-on revenue.
Why do long-term investors keep STERIS plc on the radar?
It sits at the center of global healthcare safety, a need that should grow as populations age and medical procedures increase.
- Five-year average revenue growth of 15.1%
- Expanding operating margin now at 15.9%
- Free cash flow exceeds net income by 27%
Investor takeaway
Steady compounding profile
Moderate growth plus strong cash conversion can quietly build value over 10 to 20 years.
Based on company financial statements.
What Could Change The Story
- Faded would move the profile toward Vault.
- Broke would move the profile toward Rift.
Benchmark Comparison
How has STERIS plc performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$1,301
+30.1% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| STE | +30.1% | $1,301 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame STERIS plc
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to healthcare without betting on a single drug or breakthrough
- A cash-generative business with expanding margins
- A steady operator that can compound over decades
Be Careful If You Expect
- Explosive double-digit growth every year
- A pure high-yield dividend play, since dividends are minimal
- Immunity from regulatory scrutiny in healthcare
What To Watch Over Time
- Whether operating margin stays above 15% and continues expanding
- Consistency of free cash flow staying above reported earnings
- Disciplined acquisitions that strengthen, not dilute, returns
BinaPrint Position
Where does STERIS plc sit on the BinaPrint map right now?
Test whether business quality and financial profile match the company's stated narrative.
Advanced BinaPrint details
Open the axes, investor fit, and risk framing behind this profile.
Key Metrics
Which metrics matter most for STERIS plc right now?
Three durable business metrics that matter more than day-to-day price moves.
15.1% five-year average
7.6% five-year average
44.0% gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | 15.1% five-year average | Shows whether the business has been expanding fast enough to create more long-term value. |
| EPS Growth | 7.6% five-year average | Shows whether earnings per share are compounding for owners over time. |
| Margin Quality | 44.0% gross margin | Shows how much room the business has to fund growth, absorb shocks, and stay profitable. |
Based on company financial statements.
Fundamentals
What do STERIS plc's fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
6.4% ROIC
44.0% gross margin
14.3% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 6.4% ROIC | The business is currently showing poor capital efficiency. |
| Profitability | 44.0% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 14.3% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold STERIS plc?
STERIS plc currently appears in these ETF and fund proxies.
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about STERIS plc?
Company-specific questions readers often ask about STERIS plc.
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
STERIS plc makes and services sterilization and infection prevention equipment used by hospitals, surgery centers, and pharmaceutical manufacturers.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
Infection control standards are rising globally, and hospitals cannot cut sterilization without risking lives and lawsuits, creating durable demand for STERIS equipment and service...
An installed base of equipment creates recurring service revenue, making customer relationships sticky and reducing volatility over time.
Five-year average revenue growth of 15.1% shows the company can expand meaningfully when combining organic growth with acquisitions.
Strong cash generation, with free cash flow 27% higher than net income, gives management firepower for disciplined expansion.
Bear case
What can break
Technological disruption, such as radically cheaper or decentralized sterilization methods, could reduce demand for centralized equipment and services.
Heavy reliance on healthcare spending means reimbursement cuts or hospital budget pressures could delay equipment purchases.
Large acquisitions, if mispriced or poorly integrated, could erode margins and burden the balance sheet over a decade.
A major regulatory failure or contamination event tied to its services could damage trust and invite costly litigation.
Risk Radar
Key Risks
Where downside pressure can build.
Healthcare spending exposure, a broad slowdown in hospital capital budgets could pressure the 6.2% year-over-year revenue growth rate.
Margin sensitivity, operating margin is 15.9%, a 3 point drop would materially reduce net income given the 11.3% net margin.
Acquisition risk, with 0.4 billion dollars in annual capital spending, misallocated capital could weigh on returns for years.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $230.51
- Daily move
- -3.35%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.